

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 2503

Group Art Unit:

1806

Serial No.:

SMITH, Craig A. et al.

Examiner:

T. Nisbet

Filed:

September 15, 1992

07/946,236

For:

METHOD OF TREATING TNF-DEPENDENT INFLAMMATION USING

TUMOR NECROSIS FACTOR ANTAGONISTS

AMENDMENT A

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231 RECEIVED (MAY 2 4 1994 GROUP 1800

Dear Sir:

In response to the Office Action dated November 3, 1993, please amend the above-identified application as follows:

In The Claims:

1. (Amended) A method for treating TNF-mediated inflammatory diseases which comprises administering to a mammal in need thereof a therapeutically effective amount of a TNF antagonist selected from the group consisting of a TNF receptor, a TNF binding protein and a chimeric antibody comprising a TNF receptor and the constant domain of an immunoglobulin molecule.

REMARKS

Reconsideration of the application is requested in view of the above amendment and the following remarks. A Petition for Three Months Extension of Time accompanies this paper and extends the period for response to May 3, 1994.

In compliance with the Examiner's request on page one of the Office Action, Applicants enclose herewith copies of the documents cited on the April 23, 1993 Information Disclosure Statement. Consideration thereof is requested.